Clinical outcomes of TS-1 chemotherapy for advanced and recurrent gastric cancer

Sung Ryol Lee, Hyung Ook Kim, Chang Hak Yoo

Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

Purpose: Titanium silicate (TS)-1 chemotherapy has been widely used against gastric cancer in Japan. The aim of the present study was to assess the efficacy and hematological safety of TS-1 as treatment for advanced and recurrent gastric cancer.

Methods: From September 2006 to February 2011, 51 advanced or recurrent gastric cancers were treated with TS-1. One course of treatment consisted of 40, 50, or 60 mg/m² of TS-1 twice a day for 28 days, followed by withdrawal for two weeks. The primary end point was progression-free survival (PFS), and the secondary end point was overall survival (OS).

Results: The disease control rate was 39.2% (complete response, 0/51; partial response, 6/51; stable disease, 14/51; progressive disease, 23/51; not evaluable, 8/51). The median PFS was 4.0 months (95% confidence interval [CI], 2.2 to 5.7); the median PFS of the advanced group was 6.0 months (95% CI, 2.8 to 9.1), and the median PFS of the recurrent group was 3.0 months (95% CI, 1.8 to 4.1). The median OS was 11.0 months (95% CI, 6.3 to 15.6); the median OS of the advanced group was 10.0 months (95% CI, 4.9 to 15.0), and the median OS of the recurrent group was 14.0 months (95% CI, 4.1 to 23.8). Grade 3 or 4 hematological toxicity occurred in three patients (5.9%), anemia occurred in two patients (3.9%), and thrombocytopenia occurred in one patient (2%).

Conclusion: TS-1 chemotherapy was safe and effective, with relatively long PFS and OS in patients with advanced and recurrent gastric cancers.

Key Words: Gastric cancer, TS-1, Progression free survival, Overall survival

INTRODUCTION

In Korea, gastric cancer is the most common form of cancer (data from the Ministry of Health & Welfare, 2008). Early detection and curative surgery can improve survival of loco-regional gastric cancer [1], but the survival rates of far advanced and recurrent gastric cancers remain very low. Various approaches have been tried for far advanced and recurrent gastric cancers, including 5-fluorouracil (5-FU). Two pivotal phase II studies performed in Japan that evaluated the use of titanium silicate (TS)-1 in advanced gastric cancer showed response rates of 44% and 49%, times to progression of 135 and 158 days, and overall survivals (OS) of 207 and 250 days, respectively [2,3]. TS-1 is based on a biochemical modulation of 5-FU and contains tegafur, gimeracil and oteracil potassium in a molar ratio of 1:0.4:1 [4]. As a result of its structure, TS-1 has an increased anti-tumor effect and fewer adverse reactions...
compared to those of 5-FU. In the present study, we investigated the outcome, adverse reactions, and characteristics of long-term survivors of far advanced and recurrent gastric cancers who had received TS-1.

**METHODS**

The present study was based on a prospectively designed database of gastric cancer patients at the Department of Surgery, Kangbuk Samsung Hospital. The ethics committee at our institution approved the protocol. Between September 2006 and February 2011, 51 patients with either far advanced (locally advanced unresectable or metastatic disease) or recurrent (loco-regional, peritoneal, hematogenous metastasis after curative resection) gastric cancer were treated with TS-1. Analyses were performed according to the intention to treat principle. The initial dosage of TS-1 was calculated based on body surface area (BSA), and the patients received one of the following oral dosages twice daily after meals: 40 mg for patients with BSA < 1.25 m², 50 mg for BSA ≥ 1.25 m² and < 1.50 m², and 60 mg for BSA ≥ 1.50 m². One cycle of therapy involved the administration of TS-1 as a single agent for 28 consecutive days, followed by 14 days without treatment. This schedule was repeated every six weeks until the occurrence of disease progression, unacceptable toxicity, or patient refusal.

Measurement of efficacy was conducted every three months using abdominal pelvic computed tomography (CT) or positron emission tomography-CT. Laboratory tests were also conducted every three months. The responses of the lesions were evaluated using the Response Evaluation Criteria In Solid Tumors. Progression-free survival (PFS) was defined as the period from the date of the first course of chemotherapy to the date of disease progression or death. OS was defined as the period from the date of the first course of chemotherapy to the date of death from any cause. If neither event had occurred at the time of the last record, the patient was censored at that time.

During all of the treatment courses, toxicity was graded according to the National Cancer Institute Common Criteria. All of the data are presented as median values with ranges. The significances of the differences between the results were tested using the Chi-square test, Fisher’s exact test, or Mann-Whitney test. P-values < 0.05 were considered statistically significant. PFS and OS were analyzed using the Kaplan-Meier method, and statistically significant differences in survival were identified using the log rank test. Statistical analysis was performed with a statistical analysis package SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA).

**RESULTS**

**Patient demographics and characteristics**

The baseline characteristics of the 51 patients are listed in Table 1. Thirty-two male and 19 female patients were evaluated in this study, and the median age was 62 years (range, 51 to 71). Most patients had a pretreatment performance status (PS) of 0 to 1, and 30 patients (58.8%) had a history of gastrectomy (23 curative resection and 7 palliative resection) before chemotherapy was initiated. On his-
Efficacy of TS-1 in gastric cancer

Table 2. Responses to treatment (n = 51)

| Classification | CR | PR | SD | PD | NE | DCR, n (%) | P-value | TDCR, n (%) |
|----------------|----|----|----|----|----|------------|---------|------------|
| Metastatic site |    |    |    |    |    |            |         |            |
| Peritoneum      | 0  | 3  | 10 | 12 | 4  | 13/29 (44.8)| 0.133   |            |
| Liver           | 0  | 2  | 1  | 7  | 0  | 7/22 (31.8) |         |            |
| Bone            | 0  | 0  | 0  | 2  | 3  | 4          |         |            |
| Others          | 0  | 1  | 3  | 2  | 1  |            |         |            |
| Disease status  |    |    |    |    |    |            |         |            |
| Far advanced    | 0  | 3  | 11 | 10 | 4  | 14/28 (50.0)| 0.095   | 20/51 (39.2)|
| Recurrent       | 0  | 3  | 3  | 13 | 4  | 6/23 (26.1) |         |            |

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluated; DCR, disease control rate; TDCR, total disease control rate.

tology, 19 patients (37.2%) had intestinal-type and 32 patients (62.8%) had diffuse-type adenocarcinoma. Major sites of metastases were the peritoneum in 29 patients (56.8%), liver in ten (19.6%), bone in five (9.8%), and other locations in seven (13.8%).

Response and survival

Disease control rates (DCR) are listed in Table 2. Of the 51 patients, six (11.8%) achieved a partial response (PR) and 14 (27.4%) achieved stable disease (SD), with a DCR of 39.2% (20/51) on the intention to treat analysis. The DCR was 46.5% (20/43) in patients with evaluable lesions. The DCR according to the site of metastasis was somewhat higher for peritoneal metastasis (44.8%) than it was at other sites (31.8%), which included liver, bone, ovary, and other sites. However, the DCR was not statistically different according to metastasis site (P = 0.133). Evaluation of the DCR by disease status revealed a value of 50.0% for the far advanced group and 26.1% for the recurrent group. The far advanced group tended to have a higher incidence of disease control; however, there was not a statistically significant intergroup difference in DCR (P = 0.095). The median OS after the initiation of TS-1 administration in all 51 patients was 11 months (95% CI, 6.4 to 15.6). The one-, two-, and three-year survival rates were 49.0%, 24.8%, and 19.8%, respectively (Fig. 1). The median PFS was 4.0 months (95% CI, 2.3 to 5.7). Patients with intestinal-type (35.8%) tended to have a higher two-year survival rate than those with diffuse-type (18.0%). There were seven patients who survived for longer than two years, and their characteristics are listed in Table 3. Five of the seven patients surviving longer than two years had a good PS of 0 or 1. Of these seven patients, five (71.4%) had intestinal-type adenocarcinoma. Surgical resection performed in six (1 palliative total gastrectomy and splenectomy, 5 curative subtotal gastrectomy) of the seven patients before the start of TS-1 chemotherapy, and the remaining patient did not undergo gastrectomy. All of seven patients have not any postoperative complication. The metastasis sites in these seven patients included the peritoneum in two and a specific organ in five. Three of the seven patients were alive with no apparent tumor progression at two years after TS-1 chemotherapy.

Fig. 1. Overall survival curve for all patients. The median survival time was 11.0 months with 1-, 2-, and 3-year survival rates of 49.0%, 24.8%, and 19.8%, respectively.
Table 3. Two-year survivors treated with TS-1

| Age (yr) | Sex | PS | HIS | Site of metastasis | Gastrectomy | Response | Cycle | Survival (mo) | Present status |
|----------|-----|----|-----|-------------------|-------------|----------|-------|---------------|----------------|
| 64       | M   | 2  | I   | Peritoneum        | -           | SD       | 12    | 26            | Dead           |
| 60       | M   | 2  | I   | Peritoneum        | +           | SD       | 6     | 39            | Alive          |
| 78       | M   | 0  | I   | Port-site         | +           | SD       | 6     | 39            | Alive          |
| 70       | F   | 1  | I   | Liver             | +           | PR       | 6     | 24            | Alive          |
| 62       | F   | 0  | I   | Liver             | +           | SD       | 9     | 27            | Dead           |
| 62       | M   | 1  | D   | Lung              | +           | SD       | 12    | 24            | Alive          |
| 51       | F   | 1  | D   | Ovary             | +           | SD       | 14    | 24            | Alive          |

PS, performance status; HIS, histology; I, intestinal type; D, diffuse type; SD, stable disease; PR, partial response.

Table 4. Hematological adverse reactions

| Toxicity     | Grade (NCI-CTC) | Grade 3/4 (%) |
|--------------|-----------------|---------------|
|              | 1   | 2 | 3 | 4 | 3/4 (| |
| Leukopenia   | 46  | 5 | 0 | 0 | 0.0  | |
| Neutropenia  | 46  | 5 | 0 | 0 | 0.0  | |
| Anemia       | 29  | 20| 1 | 1 | 3.9  | |
| Thrombocytopenia | 48 | 2 | 0 | 1 | 2.0  | |

NCI-CTC, National Cancer Institute-Common Toxicity Criteria.

Adverse reactions

The adverse reactions that occurred throughout the treatment course are shown in Table 4. Adverse reactions were mostly mild; grade 3 or 4 hematological toxicities occurred in 5.9% of patients, and grade 3 or 4 adverse reactions with anemia were seen in two patients (3.9%). Of the 51 patients, only one (2%) had a grade 4 adverse reaction, which was thrombocytopenia. There were no chemotherapy-related deaths.

DISCUSSION

In gastric cancer, early detection and curative resection can improve survival in patients with loco-regional gastric cancer [1], but far advanced or recurrent gastric cancers are mostly treated with chemotherapy. Low dose 5-FU and cisplatin treatment (FP) were frequently used in Japan in the 1990s due to their low toxicities and high anti-tumor effects [5-7]. A randomized study conducted by the European Organization for Research and Treatment of Cancer reported a median PFS of 4.1 months and a median OS of 7.2 months with FP [8]. However, the disadvantage of FP was long-term hospitalization during treatment [8,9]. Furthermore, in a Japanese phase III study, 5-FU alone was shown to provide a survival benefit almost equivalent to that of FP, with less toxicity and an apparently better quality of life. 5-FU alone has a median PFS of 1.9 months and a median OS of 7.1 months, and the median PFS and median OS achieved with FP were 3.9 months and 7.3 months, respectively [9]. In the present study, the median PFS and OS of patients receiving TS-1 chemotherapy were 4.0 and 11.0 months, respectively, which were relatively longer than those of patients treated with 5-FU alone or FP in the Japanese phase III trial.

In the present study, the DCR was 39.2%, which consisted of a PR rate of 11.8% and an SD rate of 27.5%, and OS was 11 months. Up to now, no combination chemotherapy using conventional agents has contributed to a prolonged median OS longer than ten months. When compared with previous studies using combination chemotherapy, such as FAMTX (5-FU, doxorubicin, methotrexate), FAM (5-FU, doxorubicin, mitomycin C), and FP, our results demonstrated relatively low response rates and longer OS for the treatment of advanced gastric cancer [10-12]. A reason for the difference between the low response rate and relatively high OS is that peritoneal metastasis was the predominant metastatic pattern in far advanced and recurrent gastric cancers. It is usually difficult to measure the lesions in patients with peritoneal metastasis because small nodules cannot be precisely measured using CT [13,14]. Therefore, most patients with peritoneal metastasis are regarded as having SD.

Laparoscopy is very useful for evaluating the response
of peritoneal metastasis in gastric cancer to chemotherapy [15]. However, routine and repeated use of laparoscopy is impractical. If the response to chemotherapy for peritoneal disease were measured more precisely, the ratio of PR and SD would change because TS-1 has been reported to have the potential to prolong the survival of patients with peritoneal dissemination [16,17]. An experimental study to assess the effect of TS-1 on peritoneal dissemination of gastric cancer has confirmed that a high concentration of 5-FU is maintained in intra-peritoneal tumors after TS-1 administration, and that survival time is prolonged without any decrease in oral food intake or body weight [18].

The present study shows that all of the patients treated with TS-1 had an adverse hematological reaction. However, severe, grade 3 and 4 adverse reactions only occurred in 5.9% of the patients, and this frequency was consistent with frequencies of 4.0% and 5.9% of grade 3 or more adverse reactions reported in previous studies [19,20]. The other adverse reactions were generally mild and tolerable, and dose modifications or discontinuations were rarely necessary.

In the present study, seven patients survived longer than two years. Five of those seven patients had good PS, and all had a single organ metastasis, either in the peritoneum alone or in a specific organ, such as a port site, liver, ovary, or lung. They received a median of nine cycles of TS-1 treatment, and four of the patients received second-line chemotherapy (doxifluridine or tegafur + uracil) after disease progression. Long-term treatment with TS-1 and the second-line treatment may have prolonged their survival. Three patients had PFS for two years and had a single organ metastasis, such as in a port site, the liver, or the lungs. Those were detected during follow-up using imaging studies, and local treatment, such as radio frequency ablation or resection, was immediately performed. After local control of metastasis, they were treated with TS-1.

Our previous study reported that patients with metastasis from gastric cancer may not expect long-term survival with only local control of cancer in the liver due to intrahepatic recurrence from multiple metastatic foci that originated from the primary disease [21]. Several studies have suggested that combined therapy that includes aggressive local treatment and early postoperative adjuvant chemotherapy for advanced gastric cancer with liver metastasis may allow long-term survival in selected patients [21-23]. The present study suggests that combined therapy with local control and TS-1 could increase PFS if local control of metastasis can be achieved.

Several studies have surveyed prognostic factors of advanced gastric cancer. Poor PS, liver metastases, peritoneal metastases, an elevated alkaline phosphatase level, multiple metastatic sites, and a histological diffuse-type tumor have been shown to be associated with poor survival [24-27]. The present study also shows that patients with intestinal-type histology (median survival time, 14 months; 95% CI, 6.34 to 21.65) tended to have longer survival than did those with diffuse-type (median survival time, 9 months; 95% CI, 6.34 to 21.65), although the P-value was not statistically significant (P = 0.108). Therefore, a study focusing on more optimal inclusion criteria needs to be performed.

In conclusion, TS-1 chemotherapy was safe and effective with a relatively higher DCR and longer OS in patients with far advanced and recurrent gastric cancers and TS-1 had various advantages, such as its convenient oral form and mild adverse reactions. However, a prospective randomized controlled trial with a larger number of patients needs to be performed to confirm these results.

CONFLICTES OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev 2000;26:243-55.
2. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur+0.4 M gimestat+1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
3. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II
study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000;58:191-7.

4. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602-6.

5. Kondo K, Murase M, Kodera Y, Akiyama S, Ito K, Yokoyama Y, et al. Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer. Oncology 1996;53:64-7.

6. Chung YS, Yamashita Y, Inoue T, Matsuoka T, Nakata B, Onoda N, et al. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer 1997;80:1-7.

7. Kim R, Murakami S, Ohi Y, Inoue H, Yoshida K, Toge T. A phase II trial of low dose administration of 5-fluorouracil and cisplatin in patients with advanced and recurrent gastric cancer. Int J Oncol 1999;15:921-6.

8. Vanhoefer U, Rougier P, Wilke H, Dureux MP, Lacave AJ, Van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18:2648-57.

9. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus miltomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-9.

10. Wils J. The treatment of advanced gastric cancer. Semin Oncol 1996;23:397-406.

11. Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin—a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-31.

12. Ohtsu A, Shimada Y, Yoshida S, Saito H, Seki S, Morise K, et al. Phase II study of protracted infusional 5-fluorouracil combined with cisplatin for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 1994;30A:2091-3.

13. Katai H, Maruyama K, Sasako M, Sano T, Okajima K, Kinoshita T, et al. Mode of recurrence after gastric cancer surgery. Dig Surg 1994;11:99-103.

14. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236-42.

15. Lehner T, Rudek B, Kienle P, Buhl K, Herfarth C. Impact of diagnostic laparoscopy on the management of gastric cancer: prospective study of 120 consecutive patients with primary gastric adenocarcinoma. Br J Surg 2002;89:471-5.

16. Kobayashi O, Konishi K, Kanari M, Cho H, Yoshikawa T, Tsuburaya A, et al. Unusual survival for more than 2 years with peritoneal metastases of gastric cancer. Gastric Cancer 2002;5:47-50.

17. Fujitani K, Tsujinaka T, Hiroa M. Feasibility study of S-1 for resectable gastric cancer with peritoneal seeding. Hepato-gastroenterology 2003;50:889-92.

18. Mori T, Fujisawa Y, Yano M, Tamura S, Yasuda T, Takiguchi S, et al. Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer. Gastric Cancer 2003;6 Suppl 1:13-8.

19. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. Br J Cancer 2007;97:37-42.

20. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer. Gastric Cancer 2007;10:129-34.

21. Kim HO, Hwang SI, Hong HP, Yoo CH. Radiofrequency ablation for metachronous hepatic metastases from gastric cancer. Surg Laparosc Endosc Percutan Tech 2009;19:208-12.

22. Takagi T, Nakase Y, Fukushima Y, Miyagaki T, Ishida E, Kobayashi Y, et al. Long-term disease-free survival following multimodal treatment in a patient with curatively unresectable advanced gastric cancer with metastases to the liver. Gan To Kagaku Ryoho 2010;37:2421-3.

23. Kunieda K, Saji S, Sugiyama Y, Osada S, Sano J, Nagao N, et al. Evaluation of treatment for synchronous hepatic metastases from gastric cancer with special reference to long-term survivors. Surg Today 2002;32:587-93.

24. Yoshida M, Ohtsu A, Boku N, Miyata Y, Shirao K, Shimada Y, et al. Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol 2004;34:654-9.

25. Rougier P, Dureux M, Mahjoubi M, Pignon JP, Bellefquih S, Oliveira J, et al. Efficacy of combined 5-fluorouracil and cisplatin in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 1994;30A:1263-9.

26. Louvet C, Carrat F, Mal F, Mabro M, Beerblock K, Vaillant JC, et al. Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). Cancer Invest 2003;21:14-20.

27. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophageal-gastric cancer: pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:2395-403.